SMTI (Sanara MedTech) Long-Term Debt: $46.2 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SMTI Sanara MedTech Inc SMTI
72 GF Score
Price $24.73
GF Value $45.77
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Sanara MedTech Long-Term Debt?

Sanara MedTech SMTI +4.54% 72 Long-Term Debt is $46.2 Mil as of Mar. 2026. GuruFocus rates SMTI with a GF Score™ of 72/100 and a GF Value™ of $45.77 (Possible Value Trap). The stock has 6 warning signs investors should review.

Sanara MedTech's Long-Term Debt for the quarter that ended in Mar. 2026 was $46.2 Mil.

Sanara MedTech's quarterly Long-Term Debt increased from Sep. 2025 ($45.1 Mil) to Dec. 2025 ($46.0 Mil) and increased from Dec. 2025 ($46.0 Mil) to Mar. 2026 ($46.2 Mil).

Sanara MedTech's annual Long-Term Debt increased from Dec. 2023 ($9.1 Mil) to Dec. 2024 ($30.7 Mil) and increased from Dec. 2024 ($30.7 Mil) to Dec. 2025 ($46.0 Mil).

Sanara MedTech  (NAS:SMTI) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Sanara MedTech Long-Term Debt Related Terms

Sanara MedTech Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Sanara MedTech's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanara MedTech Long-Term Debt Chart

Sanara MedTech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 9.11 30.69 45.97

Sanara MedTech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.40 44.22 45.09 45.97 46.23
SMTI
72GF Score
Sanara MedTech Inc SMTI
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $46.2 Mil mean?
Sanara MedTech (SMTI) has a Long-Term Debt of $46.2 Mil as of Mar. 2026.
Is Sanara MedTech's Long-Term Debt too high?
Sanara MedTech's current Long-Term Debt is $46.2 Mil. Overall, Sanara MedTech has a GF Score™ of 72/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sanara MedTech's Long-Term Debt compare to EMBC and KRMD?
Sanara MedTech's Long-Term Debt of $46.2 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Sanara MedTech's current Long-Term Debt is $46.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanara MedTech stock overvalued right now?
Based on GuruFocus' analysis, Sanara MedTech (SMTI) is currently considered Possible Value Trap. The stock's GF Value™ is $45.77, compared to a current price of $24.73 — trading 46% below its estimated fair value. The current Long-Term Debt is $46.2 Mil. Sanara MedTech's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Sanara MedTech (SMTI), the current Long-Term Debt is $46.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanara MedTech (SMTI) Overvalued in 2026?

Based on GuruFocus' analysis, Sanara MedTech stock appears to be undervalued. The current stock price of $24.73 is trading 46% below its estimated GF Value™ of $45.77. GuruFocus considers Sanara MedTech to be Possible Value Trap.

Key valuation signals for SMTI:

  • Long-Term Debt: $46.2 Mil
  • GF Value™: $45.77 vs. price of $24.73 (46% below fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the SMTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanara MedTech Business Description

Address 1200 Summit Avenue, Suite 414, Fort Worth, TX, USA, 76102
Sanara MedTech Inc is a medical technology company focused on developing and commercializing technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. It markets and sells soft tissue repair and bone fusion products for use in operating rooms and sterile environments. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen used in management of surgical wounds, and BIASURGE Surgical Solution, a sterile no-rinse solution for wound irrigation, while its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive implant that supports bone growth, and ALLOCYTE Plus Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers.
72GF Score

Get the complete analysis for SMTI

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.73
Price
$45.77
GF Value